Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
NCT ID: NCT01406704
Last Updated: 2011-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
26 participants
INTERVENTIONAL
2004-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
NCT00492700
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486
An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)
NCT04193982
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
NCT02605616
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
NCT04147195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Control: no intervention
* Rosiglitazone: rosiglitazone (8 mg/day)
* alpha-lipoic acid: alpha-lipoic acid (1800 mg/day)
* Rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No interventions assigned to this group
Rosiglitazone
Rosiglitazone (8 mg/day)
Rosiglitazone
Rosiglitazone (8 mg/day)
alpha-lipoic acid
alpha-lipoic acid (1800 mg/day)
alpha-lipoic acid
alpha-lipoic acid (1800 mg/day)
Rosiglitazone/alpha-lipoic acid
combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
Rosiglitazone/alpha-lipoic acid
combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosiglitazone
Rosiglitazone (8 mg/day)
alpha-lipoic acid
alpha-lipoic acid (1800 mg/day)
Rosiglitazone/alpha-lipoic acid
combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* viral hepatitis B and C
* autoimmune hepatitis
* Wilson's disease
* hemochromatosis
* alpha-1 antitrypsin deficiency
* breast-feeding or pregnant females
* subjects planning to become pregnant
* severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems)
* those not consenting for the study
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Seoul St. Mary's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seoul St. Mary's Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kun Ho Yoon
Role: PRINCIPAL_INVESTIGATOR
Seoul St. Mary's Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KCMC-04-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.